Acquisitions, R&D Progress, and Financial Results - Research Report on Allergan, Cubist, CHS, Charles River Laboratories, and Cynosure

Mon Aug 5, 2013 8:01am EDT

* Reuters is not responsible for the content in this press release.

Acquisitions, R&D Progress, and Financial Results - Research Report on Allergan, Cubist, CHS, Charles River Laboratories, and Cynosure

PR Newswire

NEW YORK, August 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom

Today, Analysts' Corner announced new research reports highlighting Allergan, Inc. (NYSE: AGN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Community Health Systems Inc. (NYSE: CYH), Charles River Laboratories International, Inc. (NYSE: CRL), and Cynosure, Inc. (NASDAQ: CYNO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Allergan, Inc. Research Report On July 31, 2013, Allergan, Inc. (Allergan) reported its Q2 2013 financial results. Total product net sales increased 10.6% YoY to approximately $1.6 billion. Net earnings attributable to Allergan were $359.9 million or $1.19 per diluted share compared to $295.4 million or $0.96 per diluted share in Q2 2012. David E. I. Pyott, Allergan's Chairman of the Board and CEO, said, "In the second quarter, double digit sales and earnings growth is in line with our long term growth aspirations. We are also pleased with further R&D progress with the FDA Advisory Committee's unanimous recommendation for JUVÉDERM VOLUMA XC and with the filing of OZURDEX for diabetic macular edema in both the United States and Europe." Allergan also informed that its Board of Directors has approved a dividend of $0.05 per share, for Q2 2013 payable on September 12, 2013 to stockholders of record as on August 22, 2013. The Full Research Report on Allergan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/182a_AGN]

Cubist Pharmaceuticals Inc. Research Report

On July 30, 2013, Cubist Pharmaceuticals, Inc. (Cubist) announced that it has signed a merger agreement under which it will acquire all of the outstanding shares of Optimer Pharmaceuticals Inc. (Optimer) for $10.75 per share in cash or approximately $535 million on a fully diluted basis. Cubist said that in addition to the upfront cash payment, each stockholder of Optimer will receive a Contingent Value Right (CVR), which is expected to be publicly traded, entitling the holder to receive an additional one-time cash payment of up to $5 for each share they own if certain net sales of DIFICID (fidaxomicin) are achieved, or a total transaction value of up to $801 million on a fully diluted basis. The transaction, which was approved by the Boards of Directors of both the Companies, is expected to close later in 2013, subject to regulatory and stockholder approvals along with customary closing conditions. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/92f2_CBST]

Community Health Systems Inc. Research Report

On July 30, 2013, Community Health Systems Inc. (CHS) and Health Management Associates Inc. (HMA) jointly announced that they have entered into a definitive merger agreement under which CHS will acquire HMA for approximately $7.6 billion, considering the inclusion of approximately $3.7 billion of indebtedness. The Companies informed that as per the agreement, CHS will acquire all of the issued and outstanding common stock of HMA for a combination of cash and CHS stock currently valued at $13.78 per HMA share, based on CHS' closing stock price as of July 29, 2013, and comprising of $10.50 per share in cash plus approximately 0.07 of a share of CHS common stock for each HMA share. CHS further stated that HMA shareholders would receive one Contingent Value Right (CVR) for each HMA share they own, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain issues. The Companies expect the transaction is expected to close in Q1 2014. The Full Research Report on Community Health Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7587_CYH]

Charles River Laboratories International, Inc. Research Report

On July 31, 2013, Charles River Laboratories International, Inc. (Charles River Laboratories) reported its Q2 2013 financial results. Net sales from continuing operations increased 2.9% YoY to $292.9 million. Net income attributable to common shareholders was $27.3 million or $0.56 per diluted share in Q2 2013, compared with net income attributable to common shareholders of $30.5 million or $0.63 per diluted share in Q2 2012. James C. Foster, Chairman, President and CEO, said, "We implemented actions to position the Company as the partner of choice for early-stage drug discovery and development, initiated targeted sales efforts which have enabled us to gain market share, and expanded our portfolio through strategic acquisitions." For 2013, the Company maintained its guidance to achieve net sales growth of 3% YoY to 5% YoY. Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a37e_CRL]

Cynosure, Inc. Research Report

On July 31, 2013, Cynosure, Inc. (Cynosure) reported its Q2 2013 financial results. Revenues increased 26.6% YoY to $50.1 million. Net loss was approximately $9 million or $0.54 per diluted share in Q2 2013, compared to net income of approximately $2.7 million or $0.20 per diluted share in Q2 2012. Cynosure Chairman and CEO Michael David said, "Laser product revenue increased 31% in the second quarter to $43.0 million from $32.9 million for the same period of 2012, with year over year double-digit percentage gains across each of our distribution channels - North America, Europe, Asia and our third-party international distributors. We believe our acquisition of Palomar combines two outstanding companies, creating an aesthetic industry leader with good momentum and exciting growth opportunities." The Full Research Report on Cynosure, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/6e59_CYNO]

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.